Despite a dramatic reduction in global deaths from HIV and AIDS over the last decade, approximately 1.5 million people still die from AIDS-related causes every year, more than 70 percent of them in sub-Saharan Africa. This burden falls especially hard on young women. Worldwide, rates of infection are much higher among women; in some regions, infections among adolescent girls and young women are twice that of their male counterparts.1
We are responding by advancing long-acting new options for HIV prevention.
This work includes testing an injectable formulation of rilpivirine for pre-exposure prophylaxis (PrEP). PrEP is an approach through which healthy HIV-negative people take a consistent dose of certain antiretroviral drugs to prevent infection with HIV. To help increase adherence and uptake, PATH is working with partners to test the safety and acceptability of a new long-acting injectable formulation of the antiretroviral drug rilpivirine for use as PrEP. Learn more »
1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). 2014 Gap Report fact sheet. Geneva: UNAIDS; 2014. Available at: http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet.